EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification

Daniel J Grint iD, Jasvir Dhillon, Philip D Butcher, Jack Adams, Tulika Munshi, Adam A Witney, Katherine Gould, Kenneth Laing iD, Christopher Cousins, Sean Wasserman iD, Katherine Fielding iD, Tom Harrison und 2 weitere

Clinical Infectious Diseases · 09.02.2026 · 82 (1) · e126-e134

DOI: 10.1093/cid/ciaf527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 24.09.2025. Verfasst von Daniel J Grint und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, Tuberculosis, Antitubercular Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MRC, Wellcome Trust, DFID Joint Global Health Trials Scheme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent trials have demonstrated that shortened 4-month treatment durations are effective for the majority of people with tuberculosis (TB). However, there is a population of patients with TB who require longer treatment durations. Prospectively identifying those who require shorter versus longer treatment durations would support evaluation and implementation of optimized regimens.

Methods

We analyzed data from the RIFASHORT TB treatment-shortening noninferiority trial to define a TB phenotype classification. The RIFASHORT trial primary outcome was reanalyzed using the protocol-defined noninferiority criterion of 8 percentage points, stratifying by those classified as having limited or extensive disease.

Results

Xpert MTB/RIF semiquantitative bacterial burden in combination with TB disease involvement grading on chest X-ray achieved the strongest differentiation between relapse and nonrelapse. The extensive disease TB phenotype (high semiquantitative bacterial burden and extensive TB disease on X-ray) accounted for one-quarter of the RIFASHORT trial population and more than half of all posttreatment TB relapses (13/23). For the limited TB disease phenotype (a semiquantitative bacterial burden other than high or no extensive TB disease on X-ray), the experimental 4-month 1200-mg rifampicin–containing regimen met the protocol-defined noninferiority criterion in both modified intention-to-treat (adjusted risk difference: −1.3%; 95% CI, −6.7% to 4.0%) and per protocol analyses (1.7%; 95% CI, −3.8% to 7.1%).

Conclusions

The TB phenotype classification derived here successfully identified three-quarters of RIFASHORT trial participants for whom a 4-month 1200-mg rifampicin regimen was noninferior to the 6-month standard of care. A definitive phase III randomized trial of disease-stratified rifampicin-based TB treatment is justified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinMycobacterium tuberculosisTuberculosisAntitubercular AgentsHumansMaleFemaleSeverity of Illness IndexAdultTreatment OutcomeMiddle AgedBacterial LoadRecurrence

Stichwörter der Autor:innen

TB phenotypechest X-rayrelapsesputum culturesputum smear

Substanzen

RifampinAntitubercular Agents

Autor:innen und Institutionen

  • Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Institute for Infection and Immunity, City St George's, University of London, London, United Kingdom.
  • Wellcome Discovery Research Platforms in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Afric…

ORCID-Profile: Daniel J Grint, Kenneth Laing, Sean Wasserman, Katherine Fielding

Förderung

  • MRC
  • Wellcome Trust
  • DFID Joint Global Health Trials Scheme
  • Aga Khan Foundation

Zitieren

APA

Grint, D. J., Dhillon, J., Butcher, P. D., Adams, J., Munshi, T., Witney, A. A., Gould, K., Laing, K., Cousins, C., Wasserman, S., Fielding, K., Harrison, T., Jindani, A., & RIFASHORT Study Team (2026). Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification. Clinical Infectious Diseases, 82(1), e126-e134. https://doi.org/10.1093/cid/ciaf527

Vancouver

Grint DJ, Dhillon J, Butcher PD, Adams J, Munshi T, Witney AA, et al. Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification. Clinical Infectious Diseases. 2026;82(1):e126-e134. doi:10.1093/cid/ciaf527

BibTeX
@article{Grint2026,
  author = {Grint, Daniel J and Dhillon, Jasvir and Butcher, Philip D and Adams, Jack and Munshi, Tulika and Witney, Adam A and Gould, Katherine and Laing, Kenneth and Cousins, Christopher and Wasserman, Sean and Fielding, Katherine and Harrison, Tom and Jindani, Amina and RIFASHORT Study Team, RIFASHORT Study Team},
  title = {Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {1},
  pages = {e126--e134},
  doi = {10.1093/cid/ciaf527}
}
Kostenlos starten →